Trump’s FDA Reform Agenda: Patient-Focused Approvals
A posting on the transition website takes a much milder tone than the GOP platform issued over the summer.
You may also be interested in...
Big developments, key biopharma trends, and other topics that most intrigued and impacted our readers in 2016.
CDER Director's' video advises focusing on the work and "keeping our heads down."
To call the incoming US president unpredictable would be an understatement, but that doesn’t mean that industry shouldn’t know what to expect.